Loading clinical trials...

UNKNOWNPHASE3

Mirabegron, Propevirine, Solifenacin for Treatment of Lower Urinary Tract Symptoms During Intravesical BCG Instillation

Mirabegron, Propevirine, Solifenacin for Treatment of Lower Urinary Tract Symptoms During Intravesical BCG Instillation: Prospective Randomized Controlled Trial

NCT05490082•Mansoura University

View on ClinicalTrials.gov

Summary

A randomized controlled study to compare the efficacy of mirabegron, solifenacin and propevirine for treatment of Lower urinary tract symptoms during intravesical BCG installation

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients older than age 18 years.
•Able to provide an informed consent.
•Denovo or recurrent cases with intermediate and high risk NMIBC eligible for intravesical BCG immunotherapy.
•Persistent LUTS after intravesical BCG induction.

Exclusion Criteria

•International Prostate symptom score (IPSS) greater than 20.
•Post-void residual (PVR) volume greater than 50 ml.
•Use of medications for overactive bladder.
•Pelvic surgery within the previous 6 months.
•Hypersensitivity for BCG or any of the above mentioned drugs.
•Tumor recurrence during follow up period.
•Other medical conditions that would be adversely affected by anticholinergics such as history of urinary retention due to BPH(Benign prostatic hyperplasia), constipation and history of narrow angle glaucoma.

Locations (1)

Urology and Nephrology Center, Mansoura University

Al Mansurah, Egypt

Key Dates

Start Date

March 1, 2022

Primary Completion Date

March 1, 2023

Completion Date

October 1, 2023

Last Updated

August 5, 2022

Enrollment

100

ESTIMATED participants

Conditions

Voiding Disorders

Interventions

Mirabegron, Propevirine, Solifenacin

DRUG

Contacts

Ali Abed, MSc

CONTACT

002001068896788 ali.elmenair.abed@gmail.com

Standardization of Prostatic Resection by Virtual Computational Reconstruction and Computational Flow Dynamics

NCT05941260

Prostate HyperplasiaProstatic Diseases+1 more

View study

COMPLETEDNA

Feasibility of Parasacral Transcutaneous Electrical Nerve Stimulation PTENS for Voiding Dysfunction in Peds Population

NCT04570605

Overactive BladderVoiding Disorders+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 5, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Mirabegron, Propevirine, Solifenacin for Treatment of Lower Urinary Tract Symptoms During Intravesical BCG Instillation

Inclusion Criteria

Exclusion Criteria

Standardization of Prostatic Resection by Virtual Computational Reconstruction and Computational Flow Dynamics

Feasibility of Parasacral Transcutaneous Electrical Nerve Stimulation PTENS for Voiding Dysfunction in Peds Population

Optimization of Spontaneous Postoperative Trial of Void Among Women

Multiple Sclerosis and Voiding Symptoms: How to Assess?